FDA approves Humira for treatment of psoriasis

WASHINGTON Abbott Labs has received approval from the Food and Drug Administration for its supplemental application for Humira.

The new indication for Humira (adalimumab) is for patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy. It had previously been approved as a treatment for arthritis.

A recent study by Abbott showed that Humira, when taken continuously, demonstrated a significant reduction in the signs of psoriasis.